#	Pagina
attuale pagina	/open-h2020/projects/218121/index.html

Opendata, web and dolomites

SOMIT

Leveraging a novel platform technology to develop a first-in-class immunotherapy for Celiac Disease

Total Cost €

EC-Contrib. €

Partnership

Views

Outcomes and
results

SOMIT project word cloud

Explore the words cloud of the SOMIT project. It provides you a very rough idea of what is the project "SOMIT" about.

delivered celiac proprietary netherlands ip landscape roadmap tolerizing gluten immunotherapy disciplinary investor disorder regulatory university strengthen ready therapeutic patch treat clinical institutes combined disease veterinary business czech medical therapeutics leiden navigating consolidate first republic debilitating class patients caused oromucosa world genetically consists center feasibility experimentally expand plan collaborate sublingual autoimmune intolerance agents food antigen position ex mouth proof vivo allero vitro

Project "SOMIT" data sheet

The following table provides information about the project.

Coordinator	ALLERO THERAPEUTICS Organization address address: ONDERSTRAAT 7/211 city: GENT postcode: 9070 website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.
Coordinator Country	Belgium [BE]
Project website	http://www.allerotherapeutics.com
Total cost	71˙429 €
EC max contribution	50˙000 € (70%)
Programme	1. H2020-EU.3. (PRIORITY 'Societal challenges) 2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs) 3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
Code Call	H2020-SMEInst-2018-2020-1
Funding Scheme	SME-1
Starting year	2018
Duration (year-month-day)	from 2018-09-01 to 2019-02-28

Partnership

Take a look of project's partnership.

#	participants	country	role	EC contrib. [€]
1	ALLERO THERAPEUTICS ALLERO THERAPEUTICS Organization address address: ONDERSTRAAT 7/211 city: GENT postcode: 9070 website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	BE (GENT)	coordinator	50˙000.00

Map

Project objective

Celiac Disease is a debilitating autoimmune disorder that is caused by intolerance to gluten. Although it is the most common genetically-based food intolerance in the world, there are currently no therapeutics available to treat patients. In this project, Allero Therapeutics will collaborate with two leading research institutes (Leiden University Medical Center from the Netherlands and the Veterinary Research Institute from the Czech Republic) to develop a first-in-class therapeutic against Celiac Disease. Specifically, this novel therapeutic consists of an antigen-specific immunotherapy combined with tolerizing agents, which will be delivered to the oromucosa via a proprietary sublingual mouth patch. This project consists of a 6-month multi-disciplinary feasibility study that will:

(1) experimentally demonstrate in vitro and ex vivo Proof of Principle for the novel therapeutic; (2) research all required (pre)clinical development to build a detailed roadmap for navigating the regulatory landscape; (3) strengthen and expand the current IP position; and (4) consolidate all current and future findings into an investor-ready Business Plan.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "SOMIT" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "SOMIT" are provided by the European Opendata Portal: CORDIS opendata.